Literature DB >> 8436168

Differential cytokine expression in acute and chronic murine graft-versus-host-disease.

R D Allen1, T A Staley, C L Sidman.   

Abstract

The relationship between acute and chronic graft-versus-host disease (GVHD) is not well understood. While both syndromes appear to result from recognition of host antigens by donor T cells, their pathological changes differ markedly. In light of the recent concept that helper T cells (Th) may be divided into two types based on their cytokine secretion profile and their ability to mediate cellular (Th1) or humoral (Th2) immunity, and considering the inflammatory nature of acute GVHD and the occurrence of significant B cell activation in chronic GVHD, we hypothesized that acute and chronic GVHD may be associated with differential cytokine production by activated T cells. To evaluate this hypothesis, we assessed expression of a range of cytokines in (C57BL/6 x DBA/2)F1 (B6D2F1) recipients of C57BL/6 (acute GVHD), DBA/2 (chronic GVHD) or B6D2F1 (control) spleen cells. The results reported here indicate that a wide range of cytokines, including interleukin (IL)-4, IL-10, interferon-gamma, tumor necrosis factor beta and macrophage inflammatory protein-1 alpha, are indeed differentially expressed in acute and chronic GVHD and support the concept that the pathology peculiar to acute or chronic GVHD may arise due to differential cytokine expression by activated T cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8436168     DOI: 10.1002/eji.1830230205

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  33 in total

1.  Deficiency in tumor necrosis factor alpha activity does not impair early protective Th1 responses against blood-stage malaria.

Authors:  H Sam; Z Su; M M Stevenson
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Graft-versus-host-disease-associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathway.

Authors:  T Iwasaki; T Hamano; K Saheki; T Kuroiwa; Y Kataoka; Y Takemoto; A Ogata; J Fujimoto; E Kakishita
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 3.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 4.  Superantigens related to B cell hyperplasia.

Authors:  N M Ponzio; V K Tsiagbe; G J Thorbecke
Journal:  Springer Semin Immunopathol       Date:  1996

5.  Host resistance to Listeria monocytogenes infection is enhanced but resistance to Staphylococcus aureus infection is reduced in acute graft-versus-host disease in mice.

Authors:  T Miura; D Mizuki; S Sasaki; S Hasegawa; H Sashinami; A Nakane
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

6.  Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease.

Authors:  M Murai; H Yoneyama; A Harada; Z Yi; C Vestergaard; B Guo; K Suzuki; H Asakura; K Matsushima
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

7.  Kinetics of interferon-gamma secretion and its regulatory factors in the early phase of acute graft-versus-host disease.

Authors:  H Z Hu; G L Li; Y K Lim; S H Chan; E H Yap
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

8.  In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations.

Authors:  Michael J Carlson; Michelle L West; James M Coghill; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

9.  Irradiation of the skin and systemic graft-versus-host disease synergize to produce cutaneous lesions.

Authors:  J Desbarats; T A Seemayer; W S Lapp
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

Review 10.  Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.

Authors:  Kelli P A MacDonald; Geoffrey R Hill; Bruce R Blazar
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.